
Annual report 2025
added 03-31-2026
Ra Medical Systems Revenue 2011-2026 | RMED
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Ra Medical Systems
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 819 K | 420 K | 14 K | 22 K | 4.4 M | 7.2 M | 6.26 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.2 M | 14 K | 2.73 M |
Quarterly Revenue Ra Medical Systems
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 226 K | 212 K | 143 K | - | 96 K | 93 K | 82 K | - | 133 K | 96 K | 85 K | - | 14 K | 5 K | 9 K | - | 5 K | 9 K | 1.12 M | - | 914 K | 900 K | 1.37 M | - | 1.91 M | 2.15 M | 1.75 M | - | 2.06 M | 1.24 M | 969 K | - | 1.29 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.15 M | 5 K | 675 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 13.18 | 2.93 % | $ 1.78 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 63.36 | -1.31 % | $ 3.46 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.15 | 1.18 % | $ 61.6 M | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.26 | -0.79 % | $ 51.3 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 188.66 | -0.47 % | $ 13.3 B | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.61 | -2.87 % | $ 38 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.22 | -0.16 % | $ 121 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 11.1 | -5.77 % | $ 314 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 93.88 | -1.04 % | $ 12.7 B | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.41 | -2.43 % | $ 6.68 M | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 2.13 | -1.16 % | $ 1.29 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Electromed
ELMD
|
64 M | $ 26.16 | -0.87 % | $ 221 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 329.07 | 0.48 % | $ 126 B | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.84 | -2.16 % | $ 372 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 5.46 | 2.25 % | $ 1.16 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 10.81 | -0.28 % | $ 387 M | ||
|
Varex Imaging Corporation
VREX
|
845 M | $ 12.68 | 1.2 % | $ 525 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.08 | 1.89 % | $ 18.3 M | ||
|
Vivos Therapeutics
VVOS
|
17.4 M | $ 0.88 | 4.9 % | $ 9.04 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 38.03 | -0.81 % | $ 1.18 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 54.63 | -2.98 % | $ 1.6 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 85.21 | -0.94 % | $ 2.96 B | ||
|
PAVmed
PAVM
|
71 K | $ 8.53 | -5.22 % | $ 5.72 M | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 84.54 | 0.34 % | $ 49.4 B | ||
|
MiMedx Group
MDXG
|
419 M | $ 3.36 | -2.19 % | $ 497 M |